LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback